Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legal Briefs: Concordia/Par And FTC; Amgen Off-Label Compendium Settlement

Executive Summary

FTC objected to atypical Concordia deal with Par not to launch an authorized generic in return for share of profits on Par’s generic; Amgen settlement with 49 states restricts interactions with compendium.

You may also be interested in...



Amgen Off-label Settlement Includes Exec Oversight Of Individual Product Compliance

Amgen pled guilty to off-label promotion of Aranesp, and settled civil claims of kickbacks, false price reporting and off-label promotion of other drugs; Sanofi settles claims it provided kickbacks in the form of free Hyalgan samples.

Ruth Bader Ginsburg’s Impact On Pharma, From Patents To The First Amendment

Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.

Pfizer Appears Slightly Ahead Of Moderna In COVID-19 Vaccine Race

Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel